Dexatrim Maker Says Suit Doesn't Show Harm From Carcinogen

Law360, New York (May 23, 2012, 4:16 PM EDT) -- Drugmaker Chattem Inc. asked a California federal judge Monday to toss a proposed class action accusing it of concealing the presence of a carcinogen in its Dexatrim weight loss capsules, saying the customer doesn’t even argue she was harmed by the supplement.

The Sanofi Aventis US LLC subsidiary contends that Joanne Arroyo's complaint relies on hypothetical harm from hexavalent chromium, which a March 2010 report from ConsumerLab.com said was present in Dexatrim Max.

According to the California Office of Environmental Health Hazard Assessment, the ingredient is...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

Arroyo v. Chattem, Inc.


Case Number

3:12-cv-02129

Court

California Northern

Nature of Suit

Other Statutory Actions

Judge

Charles R. Breyer

Date Filed

April 27, 2012

Law Firms

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.